The Modulatory Effects of Atomoxetine on Aberrant Connectivity During Attentional Processing in Cocaine Use Disorder

Standard

The Modulatory Effects of Atomoxetine on Aberrant Connectivity During Attentional Processing in Cocaine Use Disorder. / Nestor, Liam J; Luijten, Maartje; Ziauddeen, Hisham; Regenthal, Ralf; Sahakian, Barbara J; Robbins, Trevor W; Ersche, Karen D.

in: BIOL PSYCHIAT-COGN N, Jahrgang 9, Nr. 3, 03.2024, S. 314-325.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Nestor, LJ, Luijten, M, Ziauddeen, H, Regenthal, R, Sahakian, BJ, Robbins, TW & Ersche, KD 2024, 'The Modulatory Effects of Atomoxetine on Aberrant Connectivity During Attentional Processing in Cocaine Use Disorder', BIOL PSYCHIAT-COGN N, Jg. 9, Nr. 3, S. 314-325. https://doi.org/10.1016/j.bpsc.2023.08.003

APA

Nestor, L. J., Luijten, M., Ziauddeen, H., Regenthal, R., Sahakian, B. J., Robbins, T. W., & Ersche, K. D. (2024). The Modulatory Effects of Atomoxetine on Aberrant Connectivity During Attentional Processing in Cocaine Use Disorder. BIOL PSYCHIAT-COGN N, 9(3), 314-325. https://doi.org/10.1016/j.bpsc.2023.08.003

Vancouver

Bibtex

@article{5aa340e681514777b334f93b5463aaf8,
title = "The Modulatory Effects of Atomoxetine on Aberrant Connectivity During Attentional Processing in Cocaine Use Disorder",
abstract = "BACKGROUND: Cocaine use disorder is associated with cognitive deficits that reflect dysfunctional processing across neural systems. Because there are currently no approved medications, treatment centers provide behavioral interventions that have only short-term efficacy. This suggests that behavioral interventions are not sufficient by themselves to lead to the maintenance of abstinence in patients with cocaine use disorder. Self-control, which includes the regulation of attention, is critical for dealing with many daily challenges that would benefit from medication interventions that can ameliorate cognitive neural disturbances.METHODS: To address this important clinical gap, we conducted a randomized, double-blind, placebo-controlled, crossover design study in patients with cocaine use disorder (n = 23) and healthy control participants (n = 28). We assessed the modulatory effects of acute atomoxetine (40 mg) on attention and conflict monitoring and their associated neural activation and connectivity correlates during performance on the Eriksen flanker task. The Eriksen flanker task examines basic attentional processing using congruent stimuli and the effects of conflict monitoring and response inhibition using incongruent stimuli, the latter of which necessitates the executive control of attention.RESULTS: We found that atomoxetine improved task accuracy only in the cocaine group but modulated connectivity within distinct brain networks in both groups during congruent trials. During incongruent trials, the cocaine group showed increased task-related activation in the right inferior frontal and anterior cingulate gyri, as well as greater network connectivity than the control group across treatments.CONCLUSIONS: The findings of the current study support a modulatory effect of acute atomoxetine on attention and associated connectivity in cocaine use disorder.",
author = "Nestor, {Liam J} and Maartje Luijten and Hisham Ziauddeen and Ralf Regenthal and Sahakian, {Barbara J} and Robbins, {Trevor W} and Ersche, {Karen D}",
note = "Copyright {\textcopyright} 2023 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.",
year = "2024",
month = mar,
doi = "10.1016/j.bpsc.2023.08.003",
language = "English",
volume = "9",
pages = "314--325",
journal = "BIOL PSYCHIAT-COGN N",
issn = "2451-9022",
publisher = "Elsevier Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - The Modulatory Effects of Atomoxetine on Aberrant Connectivity During Attentional Processing in Cocaine Use Disorder

AU - Nestor, Liam J

AU - Luijten, Maartje

AU - Ziauddeen, Hisham

AU - Regenthal, Ralf

AU - Sahakian, Barbara J

AU - Robbins, Trevor W

AU - Ersche, Karen D

N1 - Copyright © 2023 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

PY - 2024/3

Y1 - 2024/3

N2 - BACKGROUND: Cocaine use disorder is associated with cognitive deficits that reflect dysfunctional processing across neural systems. Because there are currently no approved medications, treatment centers provide behavioral interventions that have only short-term efficacy. This suggests that behavioral interventions are not sufficient by themselves to lead to the maintenance of abstinence in patients with cocaine use disorder. Self-control, which includes the regulation of attention, is critical for dealing with many daily challenges that would benefit from medication interventions that can ameliorate cognitive neural disturbances.METHODS: To address this important clinical gap, we conducted a randomized, double-blind, placebo-controlled, crossover design study in patients with cocaine use disorder (n = 23) and healthy control participants (n = 28). We assessed the modulatory effects of acute atomoxetine (40 mg) on attention and conflict monitoring and their associated neural activation and connectivity correlates during performance on the Eriksen flanker task. The Eriksen flanker task examines basic attentional processing using congruent stimuli and the effects of conflict monitoring and response inhibition using incongruent stimuli, the latter of which necessitates the executive control of attention.RESULTS: We found that atomoxetine improved task accuracy only in the cocaine group but modulated connectivity within distinct brain networks in both groups during congruent trials. During incongruent trials, the cocaine group showed increased task-related activation in the right inferior frontal and anterior cingulate gyri, as well as greater network connectivity than the control group across treatments.CONCLUSIONS: The findings of the current study support a modulatory effect of acute atomoxetine on attention and associated connectivity in cocaine use disorder.

AB - BACKGROUND: Cocaine use disorder is associated with cognitive deficits that reflect dysfunctional processing across neural systems. Because there are currently no approved medications, treatment centers provide behavioral interventions that have only short-term efficacy. This suggests that behavioral interventions are not sufficient by themselves to lead to the maintenance of abstinence in patients with cocaine use disorder. Self-control, which includes the regulation of attention, is critical for dealing with many daily challenges that would benefit from medication interventions that can ameliorate cognitive neural disturbances.METHODS: To address this important clinical gap, we conducted a randomized, double-blind, placebo-controlled, crossover design study in patients with cocaine use disorder (n = 23) and healthy control participants (n = 28). We assessed the modulatory effects of acute atomoxetine (40 mg) on attention and conflict monitoring and their associated neural activation and connectivity correlates during performance on the Eriksen flanker task. The Eriksen flanker task examines basic attentional processing using congruent stimuli and the effects of conflict monitoring and response inhibition using incongruent stimuli, the latter of which necessitates the executive control of attention.RESULTS: We found that atomoxetine improved task accuracy only in the cocaine group but modulated connectivity within distinct brain networks in both groups during congruent trials. During incongruent trials, the cocaine group showed increased task-related activation in the right inferior frontal and anterior cingulate gyri, as well as greater network connectivity than the control group across treatments.CONCLUSIONS: The findings of the current study support a modulatory effect of acute atomoxetine on attention and associated connectivity in cocaine use disorder.

U2 - 10.1016/j.bpsc.2023.08.003

DO - 10.1016/j.bpsc.2023.08.003

M3 - SCORING: Journal article

C2 - 37619670

VL - 9

SP - 314

EP - 325

JO - BIOL PSYCHIAT-COGN N

JF - BIOL PSYCHIAT-COGN N

SN - 2451-9022

IS - 3

ER -